TGFb signaling is known to drive metastasis in human cancer. Under physiologic conditions, the level of TGFb activity is tightly controlled by a regulatory network involving multiple negative regulators. At metastasis, however, these inhibitory mechanisms are usually overridden so that oncogenic TGFb signaling can be overactivated and sustained. To better understand how the TGFb inhibitors are suppressed in metastatic breast cancer cells, we compared miRNA expression profiles between breast cancers with or without metastasis and found that the miR424-503 cluster was markedly overexpressed in metastatic breast cancer. Mechanistic studies revealed that miR424 and miR503 simultaneously suppressed Smad7 and Smurf2, two key inhibitory factors of TGFb signaling, leading to enhanced TGFb signaling and metastatic capability of breast cancer cells. Moreover, antagonizing miR424-503 in breast cancer cells suppressed metastasis in vivo and increased overall host survival. Interestingly, our study also found that heterogeneous expression of the miR424-503 cluster contributed to the heterogeneity of TGFb activity levels in, and metastatic potential of, breast cancer cell subsets. Overall, our findings demonstrate a novel mechanism, mediated by elevated expression of the miR424-503 cluster, underlying TGFb activation and metastasis of human breast cancer. Cancer Res; 74(21); 1-12. Ó2014 AACR.
Introduction
Breast cancer is second only to lung cancer as the cause of cancer-related deaths in women, and the vast majority of breast cancer-related deaths are due to metastatic diseases (1) . It is well established that cancer metastasis, a complex, multistep process, is driven, promoted, and modulated by aberrantly deregulated cellular signals (2) . Numerous signaling pathways, such as the Myc, b-catenin, and TGFb pathways, have been identified to play key roles in breast cancer metastasis (3) (4) (5) . Among these metastasis-associated cellular signal transduction pathways, the TGFb cascade is well documented in mediating many of the prometastatic steps (5) . High levels of TGFb or overactivated TGFb receptors have been linked to the invasiveness and metastasis of breast cancer cells (6, 7) . In contrast, low expression of TGFb receptors in breast tumors correlates with a favorable disease outcome (8) . Notably, several studies using inhibitors of TGFb have shown repression of metastasis of mammary carcinomas (9) , further highlighting a critical role of TGFb signaling in the development and progression of breast cancer metastasis.
TGFb signaling is triggered by binding of TGFb receptor ligands to a complex of transmembrane receptor serine/threonine kinases (types I and II), followed by phosphorylation of receptor-activated Smads (R-Smads). Once activated, R-Smads form a complex with a common Smad4 and translocate into the nucleus, where they regulate the transcription of target genes along with various cofactors (10) . Every step of the TGFb signaling cascade is tightly controlled by specialized factors. For example, Smad7 is key to regulating the activity of TGFb signaling via a negative feedback mechanism (11) . Smad7 was found to block the phosphorylation of Smad2/3 upon TGFb stimulation through binding to the TGFb receptor complex (12) and inhibit the heterocomplex formation between RSmads and Co-Smad (13) . Importantly, Smad7 binds to the Smad ubiquitination regulatory factor 2 (Smurf2), a member of the HECT E3 ligases family, resulting in ubiquitination of TGFb type I receptor and consequent inhibition of R-Smad activation (14) . Furthermore, Smurf2 can target R-Smads for ubiquitinmediated degradation and hence terminate R-Smads-mediated signaling (15) .
Deregulation of TGFb activation associated with decreases of its key suppressors has been found in various human cancer types. Indeed, recent evidence has shown that low-level expression of Smad7 correlates with lymph node metastasis in pancreatic cancer (16) , and knockdown of Smurf2 in human breast cancer cells results in enhanced cell migration in vitro and bone metastasis in vivo (17) , suggesting that the quantities of Smad7 and Smurf2 play an important role in modulating the level of TGFb signaling activity during the progression of tumor metastasis. How these negative regulators of TGFb signaling are decreased in cancers, however, remains poorly understood, but it remains an important area of research for future development of anti-TGFb strategies.
miRNAs are small regulatory RNA molecules that posttranscriptionally downregulate target mRNAs by interacting with their 3 0 untranslated region (UTR; ref. 18) . Differential expression of miRNA in normal and tumor tissues, or between biologic scenarios with or without metastasis, has been analyzed in a variety of cancer types (19, 20) . Our present work reports that the miR424-503 miRNA cluster might contribute to TGFb hyperactivation and thus might represent a new mechanism underlying breast cancer metastasis.
Materials and Methods

Cell culture
Breast cancer cell lines MCF7, T47D, BT474, MDA-MB-231, SKBR3, and MDA-MB-435 were purchased from ATCC in 2008, and according to the provider, the cell lines were authenticated using short tandem repeat (STR) DNA fingerprinting (21). These cell lines were grown in DMEM supplemented with 10% FBS (HyClone) in our laboratory and re-authenticated by STR fingerprinting profiles at the Forensic Medicine Department of Sun Yat-Sen University (SYSU; Guangzhou, China) in May 2014, which revealed fingerprinting profiles identical to those given in the ATCC STR database.
Clinical specimens and patient information
Paraffin-embedded human breast cancer specimens were histopathologically diagnosed at the First Affiliated Hospital of SYSU, and relevant clinical information is presented in Supplementary Table S1 . Prior donors' consents and approvals from the Institutional Research Ethics Committee were obtained. The Cancer Genome Atlas (TCGA) dataset was accessed at https://tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm.
Plasmids, infection, and transfection
Plasmids were constructed using standard methods (22) . Recombinant retrovirus production and infection were performed as previously described (23) . Transfection of plasmids or oligonucleotides was performed using the Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's instruction. For detailed description of each plasmid and sequences of synthetic oligonucleotides, see Supplementary Materials and Methods.
miRNA extraction and qPCR
Total miRNA isolation and cDNA synthesis were performed using commercial kits according to the manufacturer's instructions. miRNA expression was quantified with qPCR using miRNA-specific primers in a real-time PCR system. For details, see Supplementary Materials and Methods.
Wound-healing assay
Cells were seeded in 6-well plates and grown to 90% confluence, followed by serum starvation for 24 hours. A linear wound was created in the confluent monolayer using a pipette tip, and wounds were observed and photographed at various time points. Wound size was measured randomly at five sites perpendicular to the wound.
Transwell matrix penetration assay
Cells (2 Â 10 4 ) were plated into the top side of polycarbonate Transwell coated with Matrigel (10%; BD) and incubated at 37 C for 22 hours, followed by removal of cells inside the upper chamber with cotton swabs. Migratory and invasive cells on the lower membrane surface were fixed in 4% paraformaldehyde, stained with hematoxylin, and counted (10 random 200Â fields per well). Cell counts are expressed as the mean number of cells per field of view.
Three-dimensional spheroid invasion assay
Cells (1 Â 10 4 ) were mixed with 20% Matrigel and seeded in 24-well plates coated with 100% Matrigel (BD), and medium was changed every other day. Pictures were taken under microscope at various time points.
Western blotting and immunofluorescent assays
Western blotting and immunofluorescent assays were performed according to corresponding standard methods (24, 25) . Sources of antibodies used are given in Supplementary Materials and Methods. Fluorescence images were captured using the LSM710 confocal microscopy system (Carl Zeiss).
Luciferase assay
Cells (3.5 Â 10 4 ) were seeded and settled in 48-well plates for 24 hours. Luciferase plasmid pGL3-control-Smad7-3 0 UTR, pGL3-control-Smurf2-3 0 UTR, or pTAL-basic-3TP (100 ng each) plus 1 ng of pRL-TK plasmid (Promega) were transfected into cells. Luciferase and Renilla signals were measured 48 hours after transfection using the Dual-Luciferase Reporter Assay Kit (Promega) according to a protocol provided by the manufacturer.
RNA immunoprecipitation
Coimmunoprecipitation (co-IP) of miRNP with anti-Ago1 (Abcam) was performed as previously described (26) . Cell were lysed in buffer containing 100 mmol/L KCl, 5 mmol/L MgCl 2 , 10 mmol/L HEPES (pH 7.4), and 0.5% NP-40; and the immune complex captured by protein A agarose was washed in buffer containing 150 mmol/L KCl, 5 mmol/L MgCl 2 , 10 mmol/L HEPES (pH 7.4), and 0.1% NP-40 for 6 times. RNA extraction was performed using the RNAeasy Kit (Qiagen).
Immunohistochemical analysis
After sections were stained using anti-Smad7 (SigmaAldrich), anti-Smurf2 (Epitomics), and anti-p-Smad2 antibodies (Abcam), images were captured using the AxioVision Rel.4.6 computerized image analysis system (Carl Zeiss). The degree of immunostaining of indicated proteins was evaluated and scored as previously described (4).
Immuno-laser capture microdissection
All immuno-laser capture microdissection (LCM) tissues were prepared as previously described (27) . Samples were inspected and microdissected using Arcturus XT LCM microscope (Life Technologies Corporation). Approximately 600 cancer cells were microdissected from each slide onto a CapSure LCM cap. Total RNA and microRNA from LCM CapSure caps were extracted by QIAamp miRNeasy Mini Kit (QIAGEN GmbH) according to the manufacturer's instructions.
Tumor metastasis model
Breast cancer cell lines MCF7 (1.5 Â 10 6 ), MDA-MB-231 (1.0 Â 10 6 ), and MDA-MB-435 cells (0.8 Â 10 6 ) stably expressing firefly luciferase, alone or together with miR424-503, or corresponding control vectors, were injected intravenously via the caudal vein of BALB/c nude mice (n ¼ 5). In antagomir systemic treatment experiment, 100 mL miR424 antagomir, miR503 antagomir, or antagomir control (diluted in PBS at 2 mg/mL; Ribo Biotech) was administrated intravenously 3 times per week for 2 weeks, starting day 10 after tumor cells inoculation. For spontaneous metastasis assays, MDA-MB-435-luciferase cells (3.0 Â 10 6 ) were injected into the mammary fat pads (n ¼ 5), and antagomir was administrated intratumorally as previously described when the average volume of grown tumors reached approximately 50 mm 3 . Bioluminescence imaging was performed using the IVIS Spectrum Imaging System (Caliper Life Sciences). Image calibration and visualization were performed using the Living Image 4.2 software (Caliper Life Sciences).
Flow cytometry and single-cell cloning
Cells were dissociated into single-cell suspension, and dead cells were excluded by propidium iodide staining. Generation of single-cell-derived cultures was performed by BD Influx (BD Biosciences) single-cell plating in 96-well plates (Corning). Single, red fluorescent protein (RFP)-positive/GFP-positive cells were gated stringently. When visible cell aggregates appeared, they were transferred to flasks (Corning) and expanded.
Statistical analysis
All statistical analyses were carried out using the SPSS 11.0 statistical software package. All error bars represent mean AE SD derived from 3 independent experiments. In all cases, P < 0.05 was considered statistically significant.
Results
miR424 and miR503 are upregulated in metastatic breast cancer
To identify miRNAs differentially expressed in breast cancer metastases, we retrieved and comparatively analyzed miRNA expression profiles of metastatic versus nonmetastatic subsets from TCGA datasets. Two miRNAs, miR424 and miR503, emerged as highly upregulated miRNAs in metastatic breast cancer specimens as compared with nonmetastatic ones (Fig. 1A) . To validate these data, quantitative reverse transcription PCR (qRT-PCR) was conducted with 24 grade 4 breast cancer specimens and 93 low-grade breast cancer specimens (WHO tumor grades 1-3). Consistently, expression of miR424 or miR503 was markedly higher in grade 4 but significantly lower in low-grade, breast cancer samples (Fig. 1B) . Furthermore, breast cancer cell lines known to be highly metastatic (MDA-MB-231, SKBR3, and MDA-MB-435) displayed increases of miR424 and miR503 expression relative to non-or lowmetastatic cell lines (MCF7, T47D, and BT474; Fig. 1C ), indicating an association between miR424/miR503 high expression and breast cancer metastasis.
Notably, miR424 and miR503 levels linearly correlated with each other in breast cancer cell lines and tissue specimens ( Supplementary Fig. S1A and S1B). Furthermore, miR424 and miR503 share substantial sequence identity in their seed sequences, and their coding genes are separated by only 216 bp on the X chromosome (28) , suggesting that the miR424-503 cluster might play cooperative roles in breast cancer.
The miR424-503 cluster enhances metastasis-associated properties of breast cancer in vitro
To understand whether the miR424-503 cluster is involved in metastasis of breast cancer cells, in vitro study was performed to observe the effect of stable overexpression of the miRNAs on cellular migration and invasions ( Supplementary  Fig. S2 ). As shown in Fig. 2A , ectopic miR424, miR503, or miR424-503 enhanced the migratory ability of MCF7 and MDA-MB-231cells in wound-healing assay, and Transwell matrix penetration assay showed that miR424, miR503, or miR424-503 overexpression drastically increased the invasiveness of both cell lines (Fig. 2B) . Consistently, compared with the vector control cells, miR424-, miR503-, miR424-503 cluster-transduced cells displayed a highly aggressive penetrating growth in 3-dimensional (3D) culture (Fig. 2C) , suggesting that miR424 and miR503 are prometastatic in breast cancer cells.
Next we examined the effect of suppressing endogenous miR424 or miR503 on the phenotype of MDA-MB-231 (moderately metastatic) and MDA-MB-435 (highly metastatic) cells and found that inhibiting miR424 or miR503 markedly weakened the metastasis capability of the tested cells ( Fig. 2A-C) , further confirming the prometastatic effects of miR424 and miR503.
The miR424-503 cluster promotes metastasis of breast cancer cells in vivo
To further examine whether miR424 and miR503 promotes metastasis in vivo, luciferase-expressing MCF7 and MDA-MB-231 cells transduced with the miR424-503 cluster or control vector were injected into the caudal vein of nude mice. Strikingly, bioluminescence imaging showed that mice injected with MCF7/miR424-503 cells displayed prominent lung metastasis, whereas no visible metastasis was found in mice injected with control MCF7 cells (Fig. 3A) . Consistently, MDA-MB-231/miR424-503 mice also generated a significantly larger number of lung metastases than those in vector control cells (Fig. 3A) . To further validate whether the endogenous miR424-503 cluster was required for the observed enhanced metastasis in vivo, antagomir-424 and antagomir-503 were applied to inhibit the endogenous expression of miR424 or miR503 in the experimental metastasis assay. When the endogenous miR424 or miR503 in MDA-MB-231 and MDA-MB-435 cells was reduced by the antagomirs (Supplementary Fig. S3 ), lung metastasis of both cell lines was significantly abrogated (Fig. 3B) . Moreover, 4 of 5 mice bearing miR424-503-transduced MCF7 cells died before 50 days after inoculation, whereas only 2 mice in the vector control group died by day 56 after implantation ( Fig. 3C) . Similarly, mice injected with miR424-503-transduced MDA-MB-231 cells survived shorter than those injected with the vector control cells (Fig. 3C) . When using antagomir, inhibition of miR424 or miR503 extended mice survival (Fig. 3C) .
To investigate whether miR424-503 promotes dissemination of breast cancer cells from primary tumors, MDA-MB-435 cells were injected into the mammary gland pads of nude mice and examined for lung metastasis. As Supplementary Fig. S4A shows, while the control animals exhibited marked pulmonary metastases, antagomir treatment inhibited metastasis and prolonged the life of mice without affecting the weights of the Figure 1 . The miR424-503 cluster expression is upregulated in metastatic breast cancer. A, expression profiles of miRNA were obtained from TCGA database, and the expression levels of miR424 and miR503 were analyzed in patients with (n ¼ 31) and without metastasis (n ¼ 372). B, qPCR analysis of the expression levels of miR424 and miR503 in tumors with (n ¼ 24) and without metastatic relapse (n ¼ 93). C, relative miR424 and miR503 expression in breast cancer cell lines was analyzed by qPCR. Relative expression levels were normalized by U6 expression. ÃÃ , P < 0.01; Ã , P < 0.05.
primary tumors ( Supplementary Fig. S4B and S4C ). Together, these data indicated that the miR424-503 cluster was a strong promoter for breast cancer metastasis in vivo.
The miR424-503 cluster directly targets and suppresses multiple negative regulators of TGFb signaling In the light that the TGFb signaling is important for breast cancer metastasis, we then examined the effect of miR424-503 on TGFb activation. In cells containing the TGFb reporter gene 3TP-Lux (29) , overexpression of miR424, miR503, or miR424-503 significantly elevated, whereas inhibition of miR424 or miR503 dramatically reduced the transactivating activity of TGFb ( Supplementary Fig. S5A ). Concordantly, immunofluorescent staining showed that upon TGFb treatment, overexpression of miR424, miR503, or miR424-503 elevated the nuclear enrichment of Smad3 (Supplementary Fig. S5B ). Conversely, inhibition of miR424 or miR503 decreased the quantity of nuclear Smad3 (Supplementary Fig. S5B ). These data suggest that the miR424-503 cluster overexpression is able to enhance activity of TGFb signaling. Next, we screened for targets of miR424 and miR503 using the TargetScan Program and found that Smad7 and Smurf2, known as negative regulators of TGFb signaling, were potential target genes of miR424 and miR503 (Fig. 4A) . To validate this prediction, we found that both Smad7 and Smurf2 proteins were reduced in miR424-and/or miR503-overexpressing cells but increased by specific antagomir(s) (Fig.   4B ), whereas no detectable alterations in Smad7 or Smurf2 mRNA were seen ( Supplementary Fig. S6A and S6B ). When cells were transduced with a luciferase reporter containing Smad7 or Smurf2 3 0 UTR, ectopic expression of miR424 or miR503 decreased, whereas inhibition of miR424 or miR503 increased the activity of reporter luciferase (Fig. 4C) . Furthermore, mutations introduced to miR424 and miR503 0 UTR abrogated the suppressive effects (Fig. 4D) . Moreover, miRNP IP assay revealed high-level enrichment of Smad7 and Smurf2 transcripts in the miRNP of miR424 mimic-or miR503 mimictransfected cells (Fig. 4E) . Collectively, these results establish Smad7 and Smurf2 as targets of the miR424-503 cluster. To determine the functional significance of Smad7 and Smurf2 genes in promoting breast cancer metastasis induced by the miR424-503 cluster, we further stably expressed Smad7 open reading frame (ORF), or Smurf2 ORF, free of 3 0 UTR in miR424-503-transduced cells (Fig. 5A) . As shown in Fig. 5B , restoration of Smad7 or Smurf2 protein expression decreased invasiveness of miR424-503-transduced cells in the Transwell matrix penetration assay.
To determine the effects of Smad7 and Smurf2 on tumor metastasis in vivo, we injected mice intravenously with miR424-503/Smad7 ORF-or miR424-503/Smurf2 ORF-transduced cells, as well as their corresponding vector control cells. As shown in Fig. 5C , Smad7 or Smurf2 abrogated the metastasis-promoting effect of miR424-503, suggesting an essential role of Smad7 and Smurf2 in miR424-503-conferred breast cancer metastasis.
We then examine the clinical relevance of the miR424-503/ Smad7-Smurf2/TGFb axis in human breast cancer specimens. As shown in Fig. 5D , 78.1% (57 cases) and 67.1% (49 cases) of specimens expressing low-level miR424-503 (73 cases), respectively, exhibited high Smad7 and Smurf2 expression, whereas 56.8% (25 cases) and 50% (22 cases) of samples with high miR424-503 expression (44 cases) showed low Smad7 and Smurf2, respectively (both P < 0.05). Moreover, those cases expressing high miR424-503 displayed higher p-Smad3 levels (38 of 44 samples; 86.4%) than the low miR424-503 cases (29 of 73 samples; 39.7%; P < 0.05), suggesting that the miR424-503 cluster overexpression in clinical breast cancer lesions was associated with downregulation of Smad7 and Smurf2 and activation of TGFb.
Expression of the miR424-503 cluster correlates with TGFb activity in breast cancer
Previous evidence has suggested that the intensity of TGFb signaling is often heterogeneous in the cell population of a breast tumor, and such heterogeneity can be associated with different metastatic behaviors of breast cancer cells (30, 31) . Our current immunohistochemical study also showed that nuclear p-Smad3 staining in a breast tumor was not homogeneous (Fig. 5D) . To assess whether the differential activities of TGFb signaling were relevant to the expression levels of miR424-503, we used LCM method to obtain p-Smad3 high and p-Smad3 low loci from 10 clinical breast cancer specimens. Subsequent qRT-PCR analysis demonstrated that miR424 and miR503 levels were dramatically higher in p-Smad3 high tissues than those in p-Smad3 low tissues (Supplementary Fig. S7A ). Furthermore, we determined the intensities of TGFb signaling in various cell subsets of the MCF7, MDA-MB-231, and MDA-MB-435 breast cancer cell lines by using a lentivirally transduced TbRE-GFP reporter system (Fig. 6A) . To exclude variations in lentiviral integration sites and in copy numbers among cells, the transduced culture was single-cell-cloned. As shown in Fig. 6A , upon TGFb treatment, cells in these single-cellderived TbRE-GFP cultures showed considerable heterogeneity in TGFb signaling levels, which were not present in control cells transduced with a GFP construct driven by a constitutive CMV promoter, indicating that the heterogeneity was due to differences in TGFb-mediated transcription. Moreover, the highest and lowest 10% of TbRE-GFP-expressing cells expressed differential levels of TGFb targeted gene PAI1 (Fig.  6B ) and Smad2 and Smad3 activation levels (Fig. 6C) . These results are consistent with the previous finding that cells derived from the same breast tumor are heterogeneous in their TGFb activity.
Most notably, the protein levels of Smad7 and Smurf2 significantly decreased in TbRE-GFP high cells, as compared with those in TbRE-GFP low cells (Fig. 6C) , whereas their mRNA levels showed no significant difference between TbRE-GFP low and TbRE-GFP high cells (Supplementary Fig. S7B ). Further assessment of miR424 and miR503 quantities showed that levels of both miRNAs were dramatically higher in TbRE-GFP high cells than in TbRE-GFP low cells (Fig. 6D ). In parallel, the TbRE-GFP high cells displayed markedly higher invasiveness than the TbRE-GFP low cells in our Transwell matrix penetration assay (Fig. 6E) , strongly suggesting close correlations among miR424-503 level, TGFb activity, and cancer metastasis. Furthermore, when we transiently expressed miR424 or miR503 through transfection of their mimic oligonucleotides in TbRE-GFP low cells, increased invasiveness was observed (Fig. 6E) . In contrast, inhibition of miR424 or miR503 with inhibitory oligonucleotides decreased invasiveness of TbRE-GFP high cells (Fig. 6E) . Taken together, our data suggested that the heterogeneous TGFb activities in breast tumors might be attributable to a differential expression of the miR424-503 cluster.
Discussion
The functional significance of TGFb signaling has been well-documented in tumor metastasis (5) . TGFb activationassociated accumulation of phosphorylated Smad2 in the nucleus drives formation of bone metastasis of human breast cancer cells (31) . Clinical correlations between plasma levels of TGFb and metastatic disease have been reported in breast cancers, and low expression of TGFb receptors correlates with a favorable disease outcome (9) . The regulatory network that controls the activation level of TGFb signaling, however, remains to be understood. The finding by this current study demonstrates a new molecular mechanism by which TGFb is overactivated and thereby provides novel insights in better understanding the regulatory network of TGFb signaling.
Negative regulators of TGFb activation, including Smad7 and Smurf2, contribute to maintenance of an appropriate level of the signaling pathway under physiologic conditions (12) (13) (14) (15) . The level of Smad7 or Smurf2 has been found to be crucial in determining the activation level of TGFb signaling (17, 32) , and thus understanding what supervise their quantities in the context of cancer may reveal key mechanisms contributing to metastasis. While previous studies identified loss-of-function mutations or deletions in human cancer (33) , Smad7 or Smurf2 expression was found to be regulated also at transcriptional or posttranscriptional levels (34, 35) . Our current finding that Smad7 and Smurf2 protein levels are simultaneously and directly suppressed by overexpressed miR424-503 cluster in metastatic breast cancer cells without alterations in their mRNA levels, therefore, represents a novel posttranscriptional model for a coordinated regulation of these 2 factors. Although miRNAs have been reported to target Smad7 (36, 37) , and miR424 or miR503 overexpression has been separately found to be associated with poor prognosis in breast cancer (38, 39) , our results provides the first demonstration for miRNA More than half of the miRNAs identified in mammalian cells are clustered in genomes and transcribed as polycistronic primary transcripts, and distinct miRNAs within one cluster could work in concert to regulate a cellular process (40) . For example, both the miRNAs co-expressed from the miR144/451 cluster targeted CUGBP2 gene, and their overexpression resulted in cardioprotective effect more potently than either of them to a synergistic extent (41) . As found by the present study, both miR424 and miR503 targeted the 3 0 UTRs of Smad7 and Smurf2 mRNA, and overexpression of either one miRNA of the cluster individually decreased the protein levels of Smad7 and Smurf2, but a combined overexpression of miR424 and miR503 displayed more potent inhibitory effects. Apparently, it would be of interest to elucidate whether they have overlapping biologic functions.
Interestingly, Oneyama reported that downregulation of miR424-503 promotes mTORC2 formation and enhances growth and invasion of colon cancer through upregulating Rictor (42) . To test whether miR424-503 changes Rictor expression in breast cancer, we analyzed Rictor levels in MCF7 and MDA-MB-231 cells overexpressing miR424 and miR503 and found no detectable alteration in Rictor expression (data not shown), suggesting that these miRNAs may have distinct functions in different cell types. Such discrepant effects of an miRNA in different cell types are not uncommon (43) (44) (45) , and the underlying molecular mechanisms are still unclear. Particularly, it remains to be studied whether, and what, other cell-specific genetic/epigenetic events are involved in determining the role of an miRNA in modulating its target genes.
Our study also investigated the heterogeneity of TGFb activity in human breast cancer and found biologically as well as clinically relevant correlations among TGFb activity, miR424-503 expression, and metastatic potential in various subsets of tumor cells in a population. As metastasis is a highly inefficient process, and usually only a small fraction of cancer cells derived from the primary tumors can eventually form metastases in distant organ sites (46) , identifying cells or tumor tissues with high miR424-503 expression might be useful for predicting metastatic potential and for identifying the cell population with the highest probability to form metastases in distant organ sites. Whether these tumors and cell populations should represent the major targets for antimetastasis therapies remains to be further studied.
Apparently, additional work is required to elucidate the mechanisms underlying the heterogeneous expression of miR424-503 in breast cancer lesions. Interestingly, it was reported that miR424 could be regulated by PU.1, a member of Ets transcription factor family (47) , and hypoxia could regulate PU.1 to drive miR424 expression (48) . As breast tumor cells are exposed to heterogeneous oxygen pressure (49, 50) , whether such microenvironmental factors contribute to the heterogeneity of PU.1 levels, and consequently to the heterogeneous TGFb activation, needs to be investigated in the context of breast cancer metastasis.
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